
===== DOI 10.1016/j.oraloncology.2025.107825 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41421245</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>173</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma.</ArticleTitle><Pagination><StartPage>107825</StartPage><MedlinePgn>107825</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107825</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00654-2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To develop a retropharyngeal lymph node (RLN)-based scoring system using anatomical features and to evaluate its utility in optimizing N classification in patients with nasopharyngeal carcinoma (NPC).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This retrospective cohort study included patients with nonmetastatic NPC treated at two tertiary referral cancer centers in China between January 2012 and December 2018. Univariate and multivariate analyses were used to evaluate the association between MRI-based RLN features and multiple survival endpoints. A simplified RLN risk scoring (RRS) system (incorporating RLN multiplicity, MID, adENE and CNN) was developed in SYSUCC cohort and validated in the GMUCH cohort. A new N classification system was proposed and compared with the 9th edition of AJCC N staging system using C-index.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Positive RLNs were observed in 68.3&#xa0;% of all patients, including 66.7&#xa0;% (690/1035) in the SYSUCC cohort and 72.0&#xa0;% (340/472) in the GMUCH cohort. High RRS (defined as RRS &gt; 2) was independently associated with worse OS (hazard ratio [HR], 2.22; 95&#xa0;% CI, 1.56-3.15, P&#xa0;&lt;&#xa0;0.001), PFS (HR, 2.45; 95&#xa0;% CI, 1.87-3.20, P&#xa0;&lt;&#xa0;0.001), DMFS (HR, 2.71; 95&#xa0;% CI, 1.88-3.91, P&#xa0;&lt;&#xa0;0.001), and RFS (HR, 2.20; 95&#xa0;% CI, 1.51-3.20, P&#xa0;&lt;&#xa0;0.001). The proposed N classification system incorporated high RRS as a criterion for N3 disease, demonstrated higher C-index values compared with the 9th edition AJCC staging system for OS (0.666 vs 0.659), PFS (0.659 vs 0.639), DMFS (0.682 vs 0.663), and RFS (0.644 vs 0.629).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High RRS was strongly correlated with inferior survival outcomes in NPC patients. Integrating high RRS into the current staging system by reclassifying these patients as N3 might improve prognostic stratification and offer more precise treatment guidance.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Jing-Ni</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology,Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jia-Yu</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chuan-Run</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Liang-Ru</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Nian</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuang</LastName><ForeName>Yu-Wen</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Yu-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Meng-Wen</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Shu-Hui</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Longjunyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology,Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Yan-Qun</ForeName><Initials>YQ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: guoxiang@sysucc.org.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Wei-Xiong</ForeName><Initials>WX</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: xiawx@sysucc.org.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AJCC 9th edition</Keyword><Keyword MajorTopicYN="N">Advanced extranodal extension</Keyword><Keyword MajorTopicYN="N">Magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">Nasopharyngeal carcinoma</Keyword><Keyword MajorTopicYN="N">Retropharyngeal lymph node</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>21</Day><Hour>1</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>21</Day><Hour>1</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>20</Day><Hour>18</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41421245</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107825</ArticleId><ArticleId IdType="pii">S1368-8375(25)00654-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107819 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41401590</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Trans-hairline robotic neck dissection and robotic microvascular free flap reconstruction in oral cavity cancer.</ArticleTitle><Pagination><StartPage>107819</StartPage><MedlinePgn>107819</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107819</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00648-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A report on the feasibility of sequential robotic-assisted neck dissection and robotic micro-surgical free flap reconstruction via a trans-hairline approach in oral cavity cancer patients.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">A patient with cT2N0 right tongue squamous cell carcinoma is used for illustration.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A trans-hairline incision is used. Subplatysmal flaps are raised and levels I-III cervical lymph nodes are exposed. Da Vinci Xi robotic system is then docked via trans-hairline incision for neck dissection followed by trans-oral hemi-glossectomy. Skin island of free anterolateral thigh flap is used to reconstruct intra-oral mucosal defect. Flap pedicle is passed to the neck medial to mandible for microvascular anastomosis using the Symani micro-robotic surgical system via trans-hairline incision.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Trans-hairline robotic-assisted neck dissection and robotic microvascular free flap surgery is feasible and safe with good cosmetic and functional outcomes in oral cavity cancer patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Velda Ling-Yu</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Division of Head and Neck Surgery, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China. Electronic address: vlychow@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Valerie Wai-Yee</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>Division of Head and Neck Surgery, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Arthur Shing-Ho</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Division of Head and Neck Surgery, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Free flap reconstruction</Keyword><Keyword MajorTopicYN="N">Head and neck cancer</Keyword><Keyword MajorTopicYN="N">Robotic microsurgery</Keyword><Keyword MajorTopicYN="N">Robotic neck dissection</Keyword><Keyword MajorTopicYN="N">Trans-hairline incision</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: There is no financial interest in the production of this work and there is no financial relationship or commercial association with the manufacturer that might pose a conflict of interest. Informed consent has been obtained from the patients regarding the surgeries performed as well as photo taking for the purpose of subsequent publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>16</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41401590</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107819</ArticleId><ArticleId IdType="pii">S1368-8375(25)00648-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107705 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41401592</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Letter to the editor: Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort.</ArticleTitle><Pagination><StartPage>107705</StartPage><MedlinePgn>107705</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107705</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00534-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Cunxi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Electronic address: chauch101@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cohort study</Keyword><Keyword MajorTopicYN="N">Comment</Keyword><Keyword MajorTopicYN="N">Head and neck cancer</Keyword><Keyword MajorTopicYN="N">Real-World</Keyword><Keyword MajorTopicYN="N">Stroke</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>16</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41401592</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107705</ArticleId><ArticleId IdType="pii">S1368-8375(25)00534-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107822 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41401589</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Methodological considerations in profiling the immune microenvironment and HPV status of oral multiple primary cancers.</ArticleTitle><Pagination><StartPage>107822</StartPage><MedlinePgn>107822</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107822</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00651-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Affiliated Yangming Hospital of Ningbo University (Yuyao People's Hospital), Ningbo, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Affiliated Yangming Hospital of Ningbo University (Yuyao People's Hospital), Ningbo, Zhejiang, China. Electronic address: gaojingjing1026@outlook.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>16</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41401589</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107822</ArticleId><ArticleId IdType="pii">S1368-8375(25)00651-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107812 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41344153</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>03</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Refining surveillance in surgically treated HPV(+)OPSCC: The path to Risk-Adapted strategies.</ArticleTitle><Pagination><StartPage>107812</StartPage><MedlinePgn>107812</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107812</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00641-4</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jiaqian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. Electronic address: qszyoung@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jianning</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. Electronic address: eternityz@sina.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jiachuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. Electronic address: linjiachuan12@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. Electronic address: huoyan226@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>5</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>5</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41344153</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107812</ArticleId><ArticleId IdType="pii">S1368-8375(25)00641-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107798 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41317673</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>The diagnostic trade-off in post-treatment surveillance for HPV-positive oropharyngeal carcinoma.</ArticleTitle><Pagination><StartPage>107798</StartPage><MedlinePgn>107798</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107798</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00627-X</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yaling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Changzhou Geriatric Hospital Affiliated to Soochow University, Changzhou, Jiangsu, China; Department of Pharmacy, Changzhou No.7 People's Hospital, Changzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Heng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Luzhou Hospital of Traditional Chinese Medicine, Luzhou, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Ezhou Central Hospital, Ezhou, Hubei, China. Electronic address: ganxin202106@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>30</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>30</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41317673</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107798</ArticleId><ArticleId IdType="pii">S1368-8375(25)00627-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107797 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41314066</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Intrathyroid thymic carcinoma diagnosed following an odontogenic infection: Insights from a rare clinical presentation.</ArticleTitle><Pagination><StartPage>107797</StartPage><MedlinePgn>107797</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107797</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00626-8</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miyashita</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Tohoku Medical and Pharmaceutical University Hospital, 1-12-1 Fukumuro, Miyagino-ku, Sendai City, 983-8512, Japan. Electronic address: miyah@dent.tohoku.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Haruka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Tohoku Medical and Pharmaceutical University Hospital, 1-12-1 Fukumuro, Miyagino-ku, Sendai City, 983-8512, Japan. Electronic address: h.saito.169258@hosp.tohoku-mpu.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katoh</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Tohoku Medical and Pharmaceutical University Hospital, 1-12-1 Fukumuro, Miyagino-ku, Sendai City, 983-8512, Japan. Electronic address: masashi-katoh@hosp.tohoku-mpu.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujishima</LastName><ForeName>Fumiyoshi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathology, Tohoku Medical and Pharmaceutical University Hospital, 1-12-1 Fukumuro, Miyagino-ku, Sendai City, 983-8512, Japan. Electronic address: fujishima.fumiyoshi@tohoku-mpu.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohta</LastName><ForeName>Nobuo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Tohoku Medical and Pharmaceutical University Hospital, 1-12-1 Fukumuro, Miyagino-ku, Sendai City, 983-8512, Japan. Electronic address: noohta@hosp.tohoku-mpu.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>29</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>29</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>28</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41314066</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107797</ArticleId><ArticleId IdType="pii">S1368-8375(25)00626-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107824 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41418401</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Influencing factors on occurrence and prognosis of oral squamous cell carcinoma after organ transplantation.</ArticleTitle><Pagination><StartPage>107824</StartPage><MedlinePgn>107824</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107824</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00653-0</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Patients who undergo solid organ or hematopoietic stem cell transplantation are at an increased risk of developing oral squamous cell carcinoma (OSCC) due to prolonged immunosuppression. The specific characteristics and prognostic outcomes of OSCC in these post-transplant patients are not well understood. This study aims to investigate the risk, characteristics, and prognostic outcomes of OSCC in post-transplant patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study analyzed the clinical baseline characteristics of OSCC patients with pathological confirmation who had undergone organ transplantation (study group) and non-transplant OSCC patients (control group), all of whom were monitored with comprehensive follow-up. Survival outcomes, including overall survival (OS) and disease-free survival (DFS), were assessed using the Kaplan-Meier method. The Cox proportional hazards model was used to evaluate whether organ transplantation status was an independent risk factor affecting survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 103 patients were enrolled (study group, n&#xa0;=&#xa0;17; control group, n&#xa0;=&#xa0;86). The median age at OSCC diagnosis for study group was 53&#xa0;years, with tumors primarily located on the tongue (35.3&#xa0;%), buccal (17.6&#xa0;%), and gingiva (11.8&#xa0;%). Control group had a similar median age, with tumors mostly located on the tongue (64.0&#xa0;%), buccal (16.3&#xa0;%), and gingiva (8.1&#xa0;%). Except for one transplant recipient who received conservative management, all patients underwent surgical resection. Cox multivariate analysis identified tumor recurrence (p&#xa0;=&#xa0;0.002), tumor size (p&#xa0;=&#xa0;0.016), and vascular invasion (p&#xa0;=&#xa0;0.006) as significant adverse factors affecting survival.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study emphasizes the importance of organ transplantation history in managing OSCC. Regular screening is essential for early detection and improved survival, particularly under immunosuppressive conditions, in this high-risk group.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yiheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China; Institute of Oral Cancer and Precancerous Lesions, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Aroomi</LastName><ForeName>Maged Ali</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China; Institute of Oral Cancer and Precancerous Lesions, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China; Institute of Oral Cancer and Precancerous Lesions, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Saiwen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China; Institute of Oral Cancer and Precancerous Lesions, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Canhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China; Institute of Oral Cancer and Precancerous Lesions, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. Electronic address: canhuaj@csu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Basic Medicine, Central South University, Changsha 410013, China. Electronic address: wj0988@csu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">Oral squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">Solid organ transplantation</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>20</Day><Hour>0</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>20</Day><Hour>0</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>19</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41418401</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107824</ArticleId><ArticleId IdType="pii">S1368-8375(25)00653-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107818 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41385845</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>11</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Treatment and outcome for 2,111 patients with vermilion lip squamous cell carcinoma: A nationwide, population-based study from the SweHNCR.</ArticleTitle><Pagination><StartPage>107818</StartPage><MedlinePgn>107818</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107818</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00647-5</ELocationID><Abstract><AbstractText Label="BACKGROUND AND IMPORTANCE" NlmCategory="BACKGROUND">The major risk factor for vermilion lip squamous cell carcinoma (vlSCC) is excessive sunlight exposure. Population-based studies on treatment and outcome are lacking.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a nation-wide, population-based study of treatment and outcome from prospectively recorded data for 2,111 vlSCC registered in the Swedish Head and Neck Cancer Register (SweHNCR) diagnosed 2008-2022.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The age standardized incidence increased with 34&#xa0;% between 2008 and 2022, from 1.14 to 1.53 per 100,000 (19&#xa0;% for males and 55&#xa0;% for females). Median age at diagnosis was 76&#xa0;years and 72.4&#xa0;% had good performance status. Males predominated (57.1&#xa0;%). Lower lip vlSCC comprised 82.6&#xa0;% and upper 8.6&#xa0;%. Most had T1 (81.7&#xa0;%) or T2 (13.5&#xa0;%) tumors and few had regional (2.7&#xa0;%) or distant (0.1&#xa0;%) metastases. The 5-year observed overall survival was 70.5&#xa0;% (95&#xa0;% CI 68.4-72.6) and relative survival 90.8&#xa0;% (95&#xa0;% CI 88.2-93.7). Treatment data were registered in 1,948 cases and 97.5&#xa0;% (1,900) had a curative intent, whereof 88.5&#xa0;% had surgery, 7.3&#xa0;% radiotherapy, and 4.2&#xa0;% combination treatment. Recurrences were registered in 5.6&#xa0;% (48.6&#xa0;% local, 42.1&#xa0;% regional) whereof 15.9&#xa0;% after three years. Stage I recurred after median 17 (IQR 9-28) months whereas stage II and III after 10&#xa0;months (7-17 and 9-13, respectively). Advanced age (p&#xa0;&lt;&#xa0;0.001), poor performance status (p&#xa0;&lt;&#xa0;0.001), male sex (p&#xa0;=&#xa0;0.002), high stage (p&#xa0;=&#xa0;0.041), and only radiotherapy (p&#xa0;=&#xa0;0.007) remained as independent prognostic factors for mortality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Females had higher incidence increase than males. Advanced age, poor performance status, male sex, advanced disease, and radiotherapy only were independent prognostic factors for mortality.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hafstr&#xf6;m</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of ORL, Head &amp; Neck Surgery, Sk&#xe5;ne University Hospital, Lund, Sweden; Department of Clinical Sciences, Lund University, Lund, Sweden. Electronic address: anna.hafstrom@skane.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammerlid</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beran</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of ENT, N&#xc4;L, Trollh&#xe4;ttan, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olin</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncology, Ryhov County Hospital, J&#xf6;nk&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf6;gmo</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regional Cancer Center West, Region Vastra Gotaland, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farnebo</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Department of Biomedical and Clinical Sciences, Division of Sensory Organs and Communication, Linkoping University, Linkoping, Sweden; Department of Otorhinolaryngology, Region Ostergotland Anesthetics, Operations, and Specialty Surgery Center, Linkoping, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Follow-up</Keyword><Keyword MajorTopicYN="N">Head and neck cancer</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Lip malignancy</Keyword><Keyword MajorTopicYN="N">Nation-wide</Keyword><Keyword MajorTopicYN="N">Population based</Keyword><Keyword MajorTopicYN="N">Squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">Survival</Keyword><Keyword MajorTopicYN="N">Vermilion lip</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>12</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41385845</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107818</ArticleId><ArticleId IdType="pii">S1368-8375(25)00647-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107817 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41385843</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>11</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Is 55&#xa0;years an optimal age cutoff point for clinical staging in T1 papillary thyroid cancer?</ArticleTitle><Pagination><StartPage>107817</StartPage><MedlinePgn>107817</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107817</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00646-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aims to determine the optimal age cutoff for T1 papillary thyroid cancer (PTC), with a particular focus on the T1a and T1b subgroups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective review of electronic medical records was conducted to identify patients who underwent thyroidectomy at our institution from January 2013 to December 2018.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study cohort consisted of 2,862 patients, including 765 men (26.7&#xa0;%) and 2,097 women (73.3&#xa0;%). Survival analysis demonstrated significantly poorer recurrence-free survival (RFS) in patients aged&#xa0;&#x2265;55&#xa0;years (p&#xa0;&lt;&#xa0;0.001). Patients were stratified into T1 (tumor size&#xa0;&#x2264;2 cm, n&#xa0;=&#xa0;2,328) and non-T1 (tumor size&#xa0;&gt;2 cm, n&#xa0;=&#xa0;534) subgroups. Among the non-T1 subgroup, older patients exhibited significantly inferior RFS, consistent with the overall cohort (p&#xa0;&lt;&#xa0;0.001). However, this difference was not observed in the T1 subgroup (p&#xa0;=&#xa0;0.079). Within the T1 PTC subgroup, significant differences were identified between T1a and T1b patients concerning gender distribution, tumor size, clinical lymph node-positive status (cN1), total thyroidectomy, bilaterality, presence of Hashimoto's thyroiditis, central lymph node metastasis, lateral lymph node metastasis, and radioiodine treatment (all p&#xa0;&lt;&#xa0;0.05). Further analysis indicated that when stratified by an age cutoff of 65&#xa0;years, the prognosis for T1b patients was statistically significant (p&#xa0;=&#xa0;0.018), whereas the prognosis for T1a patients was not statistically significant (p&#xa0;=&#xa0;0.64).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The clinicopathologic characteristics of T1b patients differ significantly from those of T1a patients. Age may not be a critical factor in the prognostic staging system for T1a PTC patients, whereas 65&#xa0;years appears to be a more appropriate age cutoff for T1b patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Daixing</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Chongqing Medical University, No. 74, Linjiang Road, Yuzhong District, Chongqing 400010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Zhuolin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuzhong District, Chongqing 400016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Chongqing Medical University, No. 74, Linjiang Road, Yuzhong District, Chongqing 400010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Xinliang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuzhong District, Chongqing 400016, China. Electronic address: 201604@hospital.cqmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuzhong District, Chongqing 400016, China. Electronic address: springaah@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AJCC staging system</Keyword><Keyword MajorTopicYN="N">Age</Keyword><Keyword MajorTopicYN="N">Papillary thyroid cancer</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">T1 stage</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>12</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41385843</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107817</ArticleId><ArticleId IdType="pii">S1368-8375(25)00646-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107820 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41385844</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>11</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>A pilot study of a digital workflow for navigated tumor bed marking to reduce clinical target volume during adjuvant radiotherapy for oral squamous cell carcinoma.</ArticleTitle><Pagination><StartPage>107820</StartPage><MedlinePgn>107820</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107820</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00649-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The treatment of advanced-stage oral squamous cell carcinoma (OSCC) often requires adjuvant radiotherapy to improve the survival rate. Accurately defining the clinical target volume (CTV) is critical for radiation treatment to maximize the radiation dose and minimize negative side effects. However, precise planning remains difficult because of postoperative anatomical changes, which may lead to oversized volumes with increased collateral damage to adjacent tissues. The aim of this study is to suggest a digital planning algorithm to improve the precision of CTV definition.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this pilot study, intraoperative digital tracings of tumor resection margins were located in the preoperative computed tomography (CT) datasets of ten patients with advanced OSCC using the Brainlab Curve navigation system. OSCCs of the tongue were excluded from this analysis because of their unique anatomical features. The preoperative scans with digital tracings were aligned with the postoperative scans to identify the desired CTV. The digitally navigated CTVs were compared with the CTVs resulting from conventional planning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our findings demonstrated that the digital workflow can be easily integrated into the surgical procedure and provides a straightforward and reproducible method to achieve a statistically significant average reduction of 25.71% in the CTV.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This innovative approach to digital tracing of the resection margins in postoperative CT scans significantly increases the precision of CTV planning. Clinical studies will be needed to test the oncological safety compared to conventional planning algorithms and the potential for improved outcomes with respect to side effects and quality of life.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holdorf</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, University Medical Center, Goettingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schliephake</LastName><ForeName>Henning</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, University Medical Center, Goettingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Kathi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, University Medical Center, Goettingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruber</LastName><ForeName>Lennart Johannes</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, University Medical Center, Goettingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brockmeyer</LastName><ForeName>Phillipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, University Medical Center, Goettingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leu</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy and Radiation Oncology, University Medical Center, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieken</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy and Radiation Oncology, University Medical Center, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schminke</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, University Medical Center, Goettingen, Germany. Electronic address: boris.schminke@med.uni-goettingen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical target volume</Keyword><Keyword MajorTopicYN="N">Intraoperative digital tumor marking</Keyword><Keyword MajorTopicYN="N">Radiotherapy</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>12</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41385844</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107820</ArticleId><ArticleId IdType="pii">S1368-8375(25)00649-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107814 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41370870</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>09</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Patient-derived 3D organoid platform for functional assessment of GPC3-targeted CAR T cell cytotoxic activity in head and neck squamous cell carcinoma.</ArticleTitle><Pagination><StartPage>107814</StartPage><MedlinePgn>107814</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107814</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00643-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Head and neck squamous cell carcinoma (HNSCC) remains a therapeutic challenge owing to its marked heterogeneity and limited immunotherapy efficacy, underscoring the need for improved therapeutic strategies and preclinical systems supporting clinical translation.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We established a simplified and optimized 3D head and neck cancer organoid (HNCO)-chimeric antigen receptor (CAR) T cell co-culture platform that maintains uniform spheroid architecture (&gt;500&#xa0;&#x3bc;m) to recapitulate physiological hypoxia while preserving the tumor secretome. CAR T cell cytotoxic activity was assessed through multimodal readouts-structural disruption, ATP-based viability, and granzyme B secretion. Following initial organoid seeding, the workflow proceeded without physical manipulation, enabling concurrent multimodal assessment of CAR T cell activity from a single co-culture.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Analysis of The Cancer Genome Atlas (TCGA) data revealed that high glypican-3 (GPC3) expression was associated with poor survival in patients with HNSCC. We generated GPC3-targeted CAR T (GPC3-CAR T) cells. Using our co-culture platform, we evaluated the cytotoxic activity of GPC3-CAR T cells against five HNCOs harboring diverse genetic alterations and variable GPC3 expression. Organoids with high or moderate GPC3 expression consistently exhibited structural disintegration, reduced viability, and increased granzyme B secretion, whereas GPC3-low organoids showed heterogeneous responses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This proof-of-concept study introduces a patient-derived 3D organoid platform for functional assessment of CAR T cell cytotoxic activity in HNSCC. Our findings suggest that GPC3-CAR T therapy may be clinically applicable to subsets of patients with HNSCC, while emphasizing the need for functional validation to account for interpatient heterogeneity in clinical translation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Han-Na</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Rare and Pediatric Cancer Branch, Research Institute, National Cancer Center, Goyang 10408, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin-Ha</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Immuno-Oncology Branch, Research Institute, National Cancer Center, Goyang 10408, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Doeon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rare and Pediatric Cancer Branch, Research Institute, National Cancer Center, Goyang 10408, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jonghyun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bioinformatics Branch, Division of Cancer Data Science, Research Institute of National Cancer Center, Goyang 10408, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Soo Yoon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hye Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Jaehyeon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Immuno-Oncology Branch, Research Institute, National Cancer Center, Goyang 10408, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Dongkwan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bioinformatics Branch, Division of Cancer Data Science, Research Institute of National Cancer Center, Goyang 10408, the Republic of Korea; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 10408, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Yuh-Seog</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Rare and Pediatric Cancer Branch, Research Institute, National Cancer Center, Goyang 10408, the Republic of Korea; Immuno-Oncology Branch, Research Institute, National Cancer Center, Goyang 10408, the Republic of Korea; Department of Otorhinolaryngology-Head and Neck Surgery, National Cancer Center, Goyang 10408, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Man Ki</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Jin</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Immuno-Oncology Branch, Research Institute, National Cancer Center, Goyang 10408, the Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sung Yong</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Rare and Pediatric Cancer Branch, Research Institute, National Cancer Center, Goyang 10408, the Republic of Korea; Department of Otorhinolaryngology-Head and Neck Surgery, National Cancer Center, Goyang 10408, the Republic of Korea. Electronic address: sungyong.choi82@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chimeric antigen receptor T cell therapy</Keyword><Keyword MajorTopicYN="N">Coculture Techniques</Keyword><Keyword MajorTopicYN="N">Glypican-3</Keyword><Keyword MajorTopicYN="N">Head and neck squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">Patient-derived organoids</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>17</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41370870</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107814</ArticleId><ArticleId IdType="pii">S1368-8375(25)00643-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107815 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41365142</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>NOTCH1 loss promotes chemo and radio-resistance in head and neck cancer.</ArticleTitle><Pagination><StartPage>107815</StartPage><MedlinePgn>107815</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107815</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00644-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with over 700,000 new cases diagnosed annually. HPV-associated HNSCC patients generally respond well to standard therapies; however, about 15-20&#xa0;% experience recurrence, while the rate is approximately 50&#xa0;% in non-HPV-associated HNSCC. Identifying biomarkers for treatment failure is crucial for optimizing treatment strategies. Our lab's whole genome sequencing (WGS) data has identified NOTCH1 mutations as enriched in recurrent HPV-positive HNSCC cases. This study investigates whether NOTCH1 deletion confers treatment resistance in both HPV-positive and HPV-negative HNSCC models.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Four HPV-positive (HPV+) HNSCC cell lines (UWO23, UWO37, UMSCC47, and 93VU147) and two HPV-negative (HPV-) HNSCC cell lines (FaDu and Cal27) were examined. We used siRNA to knock down NOTCH1 expression, confirmed by qPCR, and then used CRISPR editing to generate stable NOTCH1 knockout (KO) cells. The knockout was validated by real-time qPCR and western blotting. Cell viability, clonogenicity, and invasiveness were then evaluated through viability, colony formation, and invasion assays.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The siRNA-mediated NOTCH1 knockdown increased cellular proliferation in both HPV+ and HPV- HNSCC lines, with similar effects observed in CRISPR-edited NOTCH1-KO cells. Colony formation and invasion assays demonstrated higher aggression and invasiveness in NOTCH1-KO cells compared to non-targeting controls (NTC). IC50 analysis showed that NOTCH1-KO cells exhibited enhanced cisplatin resistance in both HPV+ and HPV- lines, with increased radiation resistance also observed in NOTCH1-KO cells.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings indicate that NOTCH1 loss in both HPV+ and HPV- HNSCC cell lines leads to increased aggressiveness, clonogenicity, invasiveness, and resistance to chemotherapy and radiation. This suggests that NOTCH1 loss may be a potential biomarker for identifying HNSCC patients at higher risk of treatment failure, supporting a more personalized, intensive therapeutic approach.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaikh</LastName><ForeName>Mushfiq H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada; School of Medicine, University of TX - Rio Grande Valley, Edinburg, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazala</LastName><ForeName>Walid</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naimi</LastName><ForeName>Mahdi Farzad</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cecchini</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karimi</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Halema</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joris</LastName><ForeName>Krista</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Shengjie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Harrison</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Jawhri</LastName><ForeName>Mohd Wessam</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palma</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mymryk</LastName><ForeName>Joe S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada; Department of Microbiology &amp; Immunology, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Peter Yf</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Anthony C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada. Electronic address: anthony.nichols@lhsc.on.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker identification</Keyword><Keyword MajorTopicYN="N">CRISPR knockout models</Keyword><Keyword MajorTopicYN="N">Cellular migration</Keyword><Keyword MajorTopicYN="N">Cellular proliferation</Keyword><Keyword MajorTopicYN="N">HPV-associated HNSCC</Keyword><Keyword MajorTopicYN="N">Head and Neck Squamous Cell Carcinoma (HNSCC)</Keyword><Keyword MajorTopicYN="N">NOTCH1 mutation</Keyword><Keyword MajorTopicYN="N">Treatment resistance</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>1</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>1</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>9</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41365142</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107815</ArticleId><ArticleId IdType="pii">S1368-8375(25)00644-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107811 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41353940</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Integrated geriatric assessment and intervention in the head and neck oncology care pathway reduces adverse events and does not affect survival.</ArticleTitle><Pagination><StartPage>107811</StartPage><MedlinePgn>107811</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107811</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00640-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The number of older/frail patients with head and neck cancer (HNC) is increasing. They are more frail compared to patients with other malignancies. Therefore, geriatric care is increasingly integrated into the HNC care pathway. The aim of this study was to investigate how integrated geriatric care affects treatment outcomes in HNC patients irrespective of treatment intention.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study compared treatment-related adverse outcomes (grade&#xa0;&#x2265;&#xa0;2 Clavien-Dindo surgical complications and grade&#xa0;&#x2265;&#xa0;2 CTCAE (chemo)radiotoxicity), and one-year mortality in two patient cohorts. In the first cohort (2014-2016), geriatric screening was only observational i.e. without intervention. In the second cohort (2019-2020), a complete geriatric pathway was integrated into the oncological care pathway, including an onco-geriatric MDT (multidisciplinary team meeting), referral to the geriatrician with intervention, if needed. Multivariable logistic regression analysis was performed to identify factors associated with adverse events and one-year mortality, including the cohort period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This study included 640 patients; 369 from the first cohort and 271 from the second cohort. The second cohort showed significantly fewer adverse events (34.6&#xa0;%) compared to the first (65.4&#xa0;%) (OR 0.41; 95&#xa0;% CI 0.27-0.63: p&#xa0;&lt;&#xa0;0.001). Reductions were seen in surgical complications (OR 0.57; 95&#xa0;% CI 0.32-1.01) as well as (chemo)radiotoxicity (OR 0.39; 95&#xa0;% CI 0.20-0.76). No significant differences were observed in one-year mortality (OR 0.88; CI 0.59-1.48). Adverse events were significantly linked to malnutrition, advanced tumor stage and concomitant radiotherapy treatment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Integration of geriatric care in the HNC pathway reduces treatment-related adverse events, without altering one-year mortality.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Padovan</LastName><ForeName>Beniamino Vincenzoni</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: d.b.vincenzoni.padovan@umcg.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beenker</LastName><ForeName>Marleen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langendijk</LastName><ForeName>Johannes A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Laan</LastName><ForeName>Hans Paul</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Boukje A C</ForeName><Initials>BAC</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands; Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bock</LastName><ForeName>Geertrudia H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plaat</LastName><ForeName>Boudewijn E C</ForeName><Initials>BEC</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Graeff</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Center Groningen, University Medical Center for Geriatric Medicine, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Festen</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Center Groningen, University Medical Center for Geriatric Medicine, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halmos</LastName><ForeName>Gyorgy B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">(Chemo) radiotoxicity</Keyword><Keyword MajorTopicYN="N">Adverse outcomes</Keyword><Keyword MajorTopicYN="N">Frailty</Keyword><Keyword MajorTopicYN="N">Geriatric assessment</Keyword><Keyword MajorTopicYN="N">Geriatric intervention</Keyword><Keyword MajorTopicYN="N">Geriatric screening</Keyword><Keyword MajorTopicYN="N">Head and neck oncology</Keyword><Keyword MajorTopicYN="N">One-year mortality</Keyword><Keyword MajorTopicYN="N">Surgical complications</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>8</Day><Hour>1</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>8</Day><Hour>1</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>7</Day><Hour>18</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41353940</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107811</ArticleId><ArticleId IdType="pii">S1368-8375(25)00640-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107809 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41352160</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: A single-arm phase II clinical trial.</ArticleTitle><Pagination><StartPage>107809</StartPage><MedlinePgn>107809</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107809</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00638-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to evaluate the antitumor effect and safety of neoadjuvant chemotherapy plus tislelizumab (a programmed death-1 inhibitor) for the treatment of resectable locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eligible patients with stage III-IV LAOOPSCC were treated with two cycles of tislelizumab (200&#xa0;mg), albumin-bound paclitaxel (260&#xa0;mg/m<sup>2</sup>), and cisplatin (60-75&#xa0;mg/m<sup>2</sup>) with a three-week interval between each cycle; this treatment was followed by surgery and adjuvant radiotherapy or concurrent chemoradiotherapy. The primary endpoints were the major pathological response (MPR) rate and safety.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between March 2022 and June 2023, a total of 82 patients were eligible and completed two cycles of neoadjuvant therapy; 78 patients underwent imaging evaluation, and 73 underwent surgery and pathological response evaluation. Forty patients underwent de-escalation surgery for the primary tumor. Orbital floor resection was avoided in 1 patient, mandibulectomy was avoided in 5 patients, and near-total glossectomy or total glossectomy was avoided in 32 patients. An objective response rate of 67.9&#xa0;% and an MPR rate of 60.3&#xa0;% were achieved, with 34.2&#xa0;% of patients achieving a pathological complete response. With a median follow-up time of 24&#xa0;months, the two-year overall survival rate was 84.4&#xa0;%, and the two-year event-free survival rate was 76.7&#xa0;%. Treatment-related adverse events of grade 3 or 4 occurred in 11 patients (13.4&#xa0;%) during the neoadjuvant therapy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neoadjuvant tislelizumab plus chemotherapy for LAOOPSCC achieved a high pathological response rate and favorable survival metrics with an acceptable safety profile.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wen-Jie</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, PR China; National Center of Stomatology &amp; National Clinical Research Center for Oral Diseases, Beijing, PR China; Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Pu-Gen</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, PR China; National Center of Stomatology &amp; National Clinical Research Center for Oral Diseases, Beijing, PR China; Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zi-Qi</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, PR China; National Center of Stomatology &amp; National Clinical Research Center for Oral Diseases, Beijing, PR China; Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Li-Hang</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, PR China; National Center of Stomatology &amp; National Clinical Research Center for Oral Diseases, Beijing, PR China; Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jian-Yun</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>National Center of Stomatology &amp; National Clinical Research Center for Oral Diseases, Beijing, PR China; Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, PR China; Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Center of Stomatology &amp; National Clinical Research Center for Oral Diseases, Beijing, PR China; Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, PR China; Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ming-Wei</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, PR China; National Center of Stomatology &amp; National Clinical Research Center for Oral Diseases, Beijing, PR China; Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shu-Ming</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, PR China; National Center of Stomatology &amp; National Clinical Research Center for Oral Diseases, Beijing, PR China; Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Fu Xing Hospital, Capital Medical University, Beijing, PR China. Electronic address: yao_jie@mail.ccmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, PR China; National Center of Stomatology &amp; National Clinical Research Center for Oral Diseases, Beijing, PR China; Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, PR China. Electronic address: zhangjie@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">Head and neck</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Neoadjuvant</Keyword><Keyword MajorTopicYN="N">Squamous cell carcinoma</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>7</Day><Hour>0</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>7</Day><Hour>0</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>6</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41352160</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107809</ArticleId><ArticleId IdType="pii">S1368-8375(25)00638-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107813 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41349450</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer.</ArticleTitle><Pagination><StartPage>107813</StartPage><MedlinePgn>107813</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107813</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00642-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the quality of online information about human papillomavirus (HPV)-associated oropharyngeal cancer generated by a large language model with content retrieved from conventional web search and authoritative guideline-based sources.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty high-volume patient search queries were identified using global Google Trends data. For each question, responses were obtained from GPT-4 (OpenAI), the highest-ranked non-sponsored Google Search result, and leading governmental or guideline-based websites. Responses were anonymized and evaluated in a blinded manner by seven otolaryngology specialists and ten adult laypersons. Experts assessed accuracy, clarity, completeness, relevance, and usefulness; laypersons rated clarity, trustworthiness, and usefulness. Comparative analyses were performed using Friedman and Bonferroni-corrected Wilcoxon signed-rank tests, with inter-rater agreement estimated using intraclass correlation coefficients (ICC) RESULTS: ChatGPT-generated responses received higher mean ratings than Google Search across all domains for both rater cohorts (p&#xa0;&lt;&#xa0;0.001 for all comparisons). Experts rated GPT-4 and guideline-based content similarly for accuracy, completeness, and usefulness, while GPT-4 scored significantly higher for clarity and relevance (p&#xa0;&lt;&#xa0;0.01). Laypersons rated GPT-4 responses highest across all domains, with median scores of 5 versus 4 for the other sources. Inter-rater agreement was modest for subjective domains.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ChatGPT-generated information on HPV-associated oropharyngeal cancer matched the accuracy and completeness of authoritative guideline-based content and demonstrated significantly greater clarity and relevance, while outperforming conventional web search results. LLMs may help improve accessibility and consistency of online patient education when implemented with expert oversight, transparent sourcing, and ongoing quality monitoring.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hack</LastName><ForeName>Sholem</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel. Electronic address: sholemhack1@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attal</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geva</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farzad</LastName><ForeName>Armin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>City St. George's University London School of Medicine, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsleibi</LastName><ForeName>Shibli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Sheba Medical Center, Tel Hashomer, IsraelIsrael. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleh</LastName><ForeName>Naseem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Sheba Medical Center, Tel Hashomer, IsraelIsrael. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gvili</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Sheba Medical Center, Tel Hashomer, IsraelIsrael. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yogev</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Sheba Medical Center, Tel Hashomer, IsraelIsrael. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahal</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Sheba Medical Center, Tel Hashomer, IsraelIsrael. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaminer</LastName><ForeName>Benyamin Meir</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Soroka University Medical Center, POB 151, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remer</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Sheba Medical Center, Tel Hashomer, IsraelIsrael. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artificial intelligence</Keyword><Keyword MajorTopicYN="N">Digital health literacy</Keyword><Keyword MajorTopicYN="N">GPT-4</Keyword><Keyword MajorTopicYN="N">Google search</Keyword><Keyword MajorTopicYN="N">Health communication</Keyword><Keyword MajorTopicYN="N">Human papillomavirus</Keyword><Keyword MajorTopicYN="N">Large language model</Keyword><Keyword MajorTopicYN="N">Online health information</Keyword><Keyword MajorTopicYN="N">Oropharyngeal cancer</Keyword><Keyword MajorTopicYN="N">Patient education</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>6</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>6</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>5</Day><Hour>18</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41349450</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107813</ArticleId><ArticleId IdType="pii">S1368-8375(25)00642-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107790 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41337784</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Incidence of HPV-independent second primary malignancies following treatment of HPV-associated malignancy.</ArticleTitle><Pagination><StartPage>107790</StartPage><MedlinePgn>107790</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107790</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00619-0</ELocationID><Abstract><AbstractText>Second primary tumors after HPV-associated oropharyngeal squamous cell carcinoma (HPV&#xa0;+&#xa0;OPSCCa) are generally assumed to share the same HPV status as the index lesion, and current pathology guidelines discourage repeat HPV testing in recurrent disease. We retrospectively reviewed records from a tertiary academic center (2010-2024) to identify patients with a history of HPV&#xa0;+&#xa0;OPSCCa who subsequently developed an HPV-independent second primary head and neck squamous cell carcinoma. HPV status was determined by p16 immunohistochemistry, high-risk HPV DNA PCR, or RNA in situ hybridization. Eleven patients developed metachronous HPV-independent malignancies, representing an incidence of 2.5&#xa0;%. The median interval between tumors was 8.8&#xa0;years (range, 3.2-16.0&#xa0;years). Second primaries most often arose in the contralateral base of tongue (55&#xa0;%) or oral cavity (27&#xa0;%). All patients had received definitive or adjuvant radiation for the initial tumor, and 73&#xa0;% received concurrent chemotherapy. Four patients (36&#xa0;%) reported a smoking history &gt;10 pack-years. Most tumors at both time points were T1 or T2, but node-positive disease was more frequent in first primaries (82&#xa0;% vs 18&#xa0;%). Two patients developed a third HPV-independent primary tumor. These findings demonstrate that biologically discordant second primary head and neck cancers can emerge years after HPV&#xa0;+&#xa0;OPSCCa, challenging the assumption of HPV concordance and underscoring the need for long-term surveillance and reconsideration of repeat HPV testing in this population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nyirjesy</LastName><ForeName>Sarah C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Inaya</LastName><ForeName>Yana</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Selena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karadaghy</LastName><ForeName>Omar A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Derrick T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deschler</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Allen L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varvares</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisch</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit St, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faden</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richmon</LastName><ForeName>Jeremy D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States. Electronic address: jeremy_richmon@meei.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Discordant</Keyword><Keyword MajorTopicYN="N">HPV</Keyword><Keyword MajorTopicYN="N">Head and neck cancer</Keyword><Keyword MajorTopicYN="N">Human papillomavirus</Keyword><Keyword MajorTopicYN="N">Multiple primaries</Keyword><Keyword MajorTopicYN="N">Oropharyngeal cancer</Keyword><Keyword MajorTopicYN="N">Recurrence</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>17</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41337784</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107790</ArticleId><ArticleId IdType="pii">S1368-8375(25)00619-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107799 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41319400</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Establishment and characterization of a new immortalized human oral keratinocyte (HOK) cell line harboring various TP53 mutations.</ArticleTitle><Pagination><StartPage>107799</StartPage><MedlinePgn>107799</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107799</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00628-1</ELocationID><Abstract><AbstractText>Head and neck squamous cell carcinoma (HNSCC) is characterized by frequentTP53mutations, which include gain-of-function (GOF) variants that drive tumor progression and chemoresistance. While genomic evidence across multiple specimens ranging from oral pre-malignant lesions (OPL) through invasive and metastatic HNSCC indicates that TP53 loss or mutation occurs relatively early in HNSCC carcinogenesis, it has been difficult to discern how mutation of this tumor suppressor drives further tumor cell evolution and influences the tumor microenvironment to drive tumor progression. To address this question, we generated an immortalized human oral keratinocyte (iHOK) cell line expressing wt TP53 as well as TP53 mutant forms to determine how mutations impact functional and genomic characteristics of HOKs that can in turn drive their evolution to neoplastic cells. We established a novel panel of iHOK cell lines harboring distinctTP53mutations, including the high-risk C238F variant. Key results revealed significant phenotypic and molecular divergence: high-risk lines exhibited enhanced invasiveness and chemoresistance compared to low-risk counterparts. Weighted gene co-expression network analysis (WGCNA) linked high-risk mutations to pro-metastatic pathways and stress-response signatures, with the C238F line uniquely enriched for p53-related GOF mechanisms. Conversely, low-risk lines remained chemosensitive. These findings underscore the clinical relevance of mutation-specific iHOK models in determining the transcriptomic events that drive invasiveness and drug resistance and identify ways to intercept these phenotypes. By mirroring theTP53diversity observed in patient tumors, this cell line panel bridges a critical gap in head and neck carcinogenesis research, enabling mechanistic dissection of GOF phenotypes and preclinical evaluation of therapies in an array of TP53mutant cell models. Its significance lies in providing a validated, annotated resource that accelerates drug discovery and clarifies the role ofTP53mutational subtypes in HNSCC development and progression, offering a framework for future translational studies in genetically complex malignancies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: MeiZhao@mdanderson.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhiyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; LC Sciences, Houston, TX, USA. Electronic address: zliu@lcsciences.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawabe</LastName><ForeName>Mutsuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: MKawabe@mdanderson.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osman</LastName><ForeName>Abdullah A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: AAOsman@mdanderson.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frederick</LastName><ForeName>Mitchell J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Bobby R. Alford Department of Otolaryngology-Research, Head &amp; Neck Surgery, Baylor College of Medicine, Houston, TX, USA. Electronic address: mjfreder@bcm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: jmyers@mdanderson.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Gain-of-function</Keyword><Keyword MajorTopicYN="N">Immortalized human oral keratinocyte (iHOK)</Keyword><Keyword MajorTopicYN="N">Oral keratinocyte</Keyword><Keyword MajorTopicYN="N">RNA-seq</Keyword><Keyword MajorTopicYN="N">TP53 Mutations</Keyword><Keyword MajorTopicYN="N">Weighted gene co-expression network analysis (WGCNA)</Keyword><Keyword MajorTopicYN="N">p53</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>30</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41319400</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107799</ArticleId><ArticleId IdType="pii">S1368-8375(25)00628-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107789 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41314067</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Hpv-driven rewiring of the tumor immune microenvironment through single-cell profiling informs prognosis and therapy in HNSCC.</ArticleTitle><Pagination><StartPage>107789</StartPage><MedlinePgn>107789</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107789</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00618-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Human papillomavirus (HPV) status is a key prognostic factor in head and neck squamous cell carcinoma (HNSCC), yet the precise immunological mechanisms and robust biomarkers for guiding personalized therapy remain elusive. This study aims to comprehensively delineate how HPV infection reprograms the tumor immune microenvironment (TIME) and to develop a novel prognostic model for stratifying patient outcomes and therapeutic responses.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Multi-omics data from TCGA and GEO databases were integrated. The immune landscape was compared between HPV<sup>+</sup>&#xa0;and HPV<sup>-</sup> HNSCC using bulk transcriptomic deconvolution and single-cell RNA sequencing (scRNA-seq) profiling. A prognostic risk signature was constructed from HPV-associated genes via LASSO-COX regression and validated in independent cohorts. The model was evaluated for its association with immune infiltration, tumor mutational burden, and drug sensitivity. Cellular communication networks were deciphered using CellChat. Hub genes expression was confirmed by immunohistochemistry (IHC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Single-cell profiling revealed that HPV<sup>+</sup>&#xa0;tumors were characterized by an immunologically active microenvironment with increased infiltration and enhanced crosstalk of cytotoxic CD8<sup>+</sup>&#xa0;T cells, helper CD4<sup>+</sup>&#xa0;T cells, and B cells. In contrast, HPV<sup>-</sup> tumors exhibited a stromal-rich, immunosuppressive niche. We developed and validated a prognostic model based on seven HPV-related genes (IER3, FHL2, MBOAT2, DSC3, IRAK3, RGMA, BARD1). This risk score robustly stratified patients into high- and low-risk groups with distinct overall survival (low-risk vs. high-risk, P&#xa0;&lt;&#xa0;0.0001) and was an independent prognostic factor. The low-risk group, mirroring the HPV<sup>+</sup>&#xa0;phenotype, demonstrated an activated immune milieu, higher expression of immune checkpoints (e.g., PD-1, CTLA-4), and was predicted to be more responsive to both chemotherapy and immunotherapy. Conversely, the high-risk group displayed a barren immune landscape, enriched in stromal and pro-tumorigenic pathways (e.g., MIF, COLLAGEN), and heightened sensitivity to specific targeted agents (e.g., Dasatinib). IHC validation confirmed the tumor-promotive role of hub genes (IER3, FHL2).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study leverages single-cell profiling to elucidate HPV-driven immunological remodeling in HNSCC. The derived prognostic signature effectively captures the essence of the TIME, serving as a reliable biomarker for predicting patient survival and informing precision therapy, potentially bridging the gap between HPV status and clinical decision-making.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kou</LastName><ForeName>Qianzi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Chongyang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nov</LastName><ForeName>Pengkhun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Changqian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Peizan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lilin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yangfeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Duanyu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasai</LastName><ForeName>Arzoo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiqiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China. Electronic address: ljq821028@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Kunpeng</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China. Electronic address: dkp321098@smu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>29</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>29</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>28</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41314067</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107789</ArticleId><ArticleId IdType="pii">S1368-8375(25)00618-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107816 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41401591</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Patterns of metastasis and nodal disease in tongue and buccal carcinomas: Case-based reflections in Delhi NCR Region.</ArticleTitle><Pagination><StartPage>107816</StartPage><MedlinePgn>107816</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107816</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00645-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Oral squamous cell carcinoma (OSCC) is a large source of cancer-related morbidity in India especially when it involves the tongue and the buccal mucosa. Despite the fact that TNM staging provides a global framework, regional patterns of metastasis, comorbidity interaction and concordance between imaging and pathology are not uniformly represented. This study will investigate nodal disease patterns in a group of people in the Delhi National Capital Region (NCR) and will suggest more specific treatments. The research aims to facilitate early diagnosis and intervention pathways and to reduce inequality in healthcare service provision.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty patients with OSCC who had been diagnosed between 2023 and 2025 were the subjects of a retrospective study conducted on tertiary oncology centres in Delhi NCR. Inclusion criteria were confirmation of primary OSCC of the tongue or buccal mucosa, availability of PET -CT or MRI images, full TNM staging, and comorbidity information. Data visualization included heatmaps, scatter plot, cluster diagram and radar charts. Along with the imaging concordance, tumour site, the size of the lesion, nodal involvement, and the burden of comorbidity were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bilateral nodal involvement was higher in the Tongue OSCC, mostly at Level II and III, but the tumours of the buccal mucosa were mostly limited to Level Ib unilateral. Nodal burden was much higher in lesions of around 3.5&#xa0;cm. Comorbidities (diabetes and chronic kidney disease) were also related to higher FDG uptake and necrosis, but the relationships were not statistically significant. PET-CT had 85 percent agreement with the pathology of the surgery. The decision of treatment was based on the staging with surgery being the preferred treatment option in early disease and chemoradiation in advanced ones.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The site and size of tumour have a significant impact on nodal dissemination in OSCC. Bilateral neck dissection can be a wise option in case of early tongue lesions involving the midline but selective unilateral dissection is adequate in selecting cases involving the buccal lesions. It is necessary to couple comorbidity profiling with imaging results when planning pre-treatment. In this study, health systems, health equity, and collaborative oncology care are strengthened.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bajaj</LastName><ForeName>Kripa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Oral Biology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramadoss</LastName><ForeName>Ramya</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Oral Biology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, India. Electronic address: drramya268@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundar</LastName><ForeName>Sandhya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oral Biology and Oral Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvam</LastName><ForeName>Suganya Panneer</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Oral Biology and Oral Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shree K</LastName><ForeName>Hema</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oral Biology and Oral Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, India; Saveetha Institute of Basic Medical Sciences, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Good health and well-being</Keyword><Keyword MajorTopicYN="N">Head and neck cancer</Keyword><Keyword MajorTopicYN="N">Health systems strengthening</Keyword><Keyword MajorTopicYN="N">Nodal metastasis</Keyword><Keyword MajorTopicYN="N">Oral squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">Partnerships for the goals</Keyword><Keyword MajorTopicYN="N">Personalized oncology</Keyword><Keyword MajorTopicYN="N">Reduced inequalities</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>16</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41401591</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107816</ArticleId><ArticleId IdType="pii">S1368-8375(25)00645-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107810 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41391200</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>13</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Cerebrovascular events after head and neck radiation therapy: A systematic review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>107810</StartPage><MedlinePgn>107810</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107810</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00639-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Several studies have demonstrated increased risk of cerebrovascular events, including carotid stenosis, stroke &amp; transient ischemic attack, following head and neck radiation therapy (RT) for head and neck cancer (HNC). This systematic review reports the incidence of cerebrovascular events (CVEs) and the relative rate (RR) of ischemic stroke in patients treated with RT compared to non-RT populations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive database search identified publications reporting the incidence or RR of CVEs following RT. Citations were retrieved, and data was extracted where appropriate. Risk of bias was assessed, and meta-analyses were conducted to present pooled estimates of the incidence of CVEs after RT and the RR of ischemic stroke.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">2,598 citations were retrieved, of which 50 met criteria for inclusion. The incidence of carotid stenosis ranged from 0&#xa0;%-40&#xa0;% over median follow-up duration of 6-68&#xa0;months (mean&#xa0;=&#xa0;6-150&#xa0;months). The incidence of ischemic stroke was 8.98 per 1,000 person-years (95&#xa0;% CI: 4.66 - 17.30). The relative rate of ischemic stroke was higher in patients treated with radiation therapy with a HR of 1.33 (95&#xa0;% CI: 1.21 - 1.45) when compared to a reference population (HR of 1) of those treated with surgery and a HR of 1.29 (95&#xa0;% CI: 1.13 - 1.47) when compared to the general population as the reference group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HNC patients face an increased risk of ischemic stroke following head and neck radiation therapy. The magnitude of this heightened risk remains elusive in the contemporary era of intensity-modulated radiation techniques and should be addressed in future studies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayoo</LastName><ForeName>Kennedy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Toronto. Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto. Toronto, Ontario, Canada. Electronic address: kennedy.ayoo@mail.utoronto.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Elliot</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, University of Toronto. Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemure-Poliquin</LastName><ForeName>No&#xe9;mie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, University of Toronto. Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto. Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irish</LastName><ForeName>Jonathan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, University of Toronto. Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto. Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindsay</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Toronto. Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eskander</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, University of Toronto. Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto. Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>14</Day><Hour>19</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>14</Day><Hour>19</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>14</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41391200</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107810</ArticleId><ArticleId IdType="pii">S1368-8375(25)00639-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/j.oraloncology.2025.107821 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41391201</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0593</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><PubDate><Year>2025</Year><Month>Dec</Month><Day>13</Day></PubDate></JournalIssue><Title>Oral oncology</Title><ISOAbbreviation>Oral Oncol</ISOAbbreviation></Journal><ArticleTitle>Survival rates and oncologic outcomes of adeno squamous carcinoma of oral cavity: A systematic review.</ArticleTitle><Pagination><StartPage>107821</StartPage><MedlinePgn>107821</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oraloncology.2025.107821</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1368-8375(25)00650-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adenosquamous carcinoma (ASC) of the oral cavity is an uncommon and aggressive malignancy characterized by squamous and glandular histologic components. Due to its rarity, clinical behavior and oncologic outcomes remain poorly defined.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature review was conducted according to PRISMA 2020 guidelines. Comprehensive searches of Embase, PubMed, Scopus, and Cochrane Library identified studies published between 1968 and 2025.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-one patients were included. The most frequent subsites were tongue (43&#xa0;%) and floor of mouth (31&#xa0;%). Transoral surgery was performed in 93&#xa0;% of cases, with neck dissection in 50&#xa0;%. Adjuvant therapy was administered in 27&#xa0;%. Despite 57&#xa0;% presenting with early-stage disease, recurrence occurred in 42&#xa0;%: local (36&#xa0;%), regional (20&#xa0;%), and distant (10&#xa0;%). Local recurrence was significantly associated with advanced stage (p&#xa0;=&#xa0;0.007) and subsite (p&#xa0;=&#xa0;0.028), highest in floor of mouth (59&#xa0;%) and gingiva (50&#xa0;%). Perineural invasion (PNI), lymphovascular invasion (LVI), and positive margins correlated with recurrence and reduced time to recurrence (TTR), disease-specific survival (DSS), and overall survival (OS) (p&#xa0;&lt;&#xa0;0.001). Two-year TTR, DSS, and OS rates were 47&#xa0;%, 74&#xa0;%, and 70&#xa0;%, respectively-lower than reported for conventional oral squamous carcinoma. Because oral ASC is rare, the evidence is primarily derived from case reports and small retrospective series.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Oral ASC demonstrates high recurrence and poor survival, even in early-stage disease. Prognosis is strongly influenced by PNI, LVI, and margin status, as well as tumor subsite. These findings highlight oral ASC as a distinct and particularly aggressive entity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chiari</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Otolaryngology Head and Neck Unit - "Santo Spirito" Hospital, Pescara, Italy. Electronic address: francesco.chiari.med@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carobbio</LastName><ForeName>Andrea Luigi Camillo</ForeName><Initials>ALC</Initials><AffiliationInfo><Affiliation>Unit of Otorhinolaryngology - Head and Neck Surgery, Azienda Ospedale-Universit&#xe0; Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Otorhinolaryngology - Head and Neck Surgery, Azienda Ospedale-Universit&#xe0; Padova, Padova, Italy; Section of Otorhinolaryngology - Head and Neck Surgery, Department of Neuroscience (DNS), University of Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolai</LastName><ForeName>Piero</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit of Otorhinolaryngology - Head and Neck Surgery, Azienda Ospedale-Universit&#xe0; Padova, Padova, Italy; Section of Otorhinolaryngology - Head and Neck Surgery, Department of Neuroscience (DNS), University of Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caporale</LastName><ForeName>Claudio Donadio</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Otolaryngology Head and Neck Unit - "Santo Spirito" Hospital, Pescara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarino</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Otolaryngology Head and Neck Unit - "Santo Spirito" Hospital, Pescara, Italy; Department of Innovative Technologies in Medicine and Dentistry, University "G.D'Annunzio", Chieti-Pescara, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oral Oncol</MedlineTA><NlmUniqueID>9709118</NlmUniqueID><ISSNLinking>1368-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adenosquamous carcinoma</Keyword><Keyword MajorTopicYN="N">Head and neck</Keyword><Keyword MajorTopicYN="N">Oral cavity tumor</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>14</Day><Hour>19</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>14</Day><Hour>19</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>14</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41391201</ArticleId><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107821</ArticleId><ArticleId IdType="pii">S1368-8375(25)00650-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>